NCT01506882View on ClinicalTrials.gov

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2015

Conditions
EpilepsyPartial Onset Seizures
Interventions
DRUG

Levetiracetam (LEV)

"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use"

Trial Locations (27)

Unknown

19, Aomori

33, Asaka

21, Daitō

12, Fujisawa

14, Hamamatsu

11, Himeji

30, Hirosaki

8, Kagoshima

20, Kamakura

17, Kawasaki

3, Kitakyushu

26, Kodaira

9, Kokubunji

32, Kyoto

25, Miyakonojō

5, Nagoya Aichi

4, Nara

22, Okayama

15, Osaka

27, Osaka

13, Saitama

1, Sakai

29, Sapporo

24, Sayama

2, Toyonaka

7, Ube

18, Yamagata

All Listed Sponsors
lead

UCB Japan Co. Ltd.

INDUSTRY

NCT01506882 - An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy | Biotech Hunter | Biotech Hunter